Christian Cobaugh is a molecular biologist turned biotech operator who has spent more than 15 years at the frontier of genetic medicines. In January 2026 he became CEO of Alloy Genetic Medicines, the nucleic-acid division of Alloy Therapeutics, where he leads work on the AntiClastic cyclic nucleic acid platform for ASOs, siRNA, and other RNA therapeutics. He is best known for founding Vernal Biosciences, an mRNA contract manufacturer he built in Colchester, Vermont, on the premise that everyone who needs mRNA should be able to get it. Before Vernal he was the first scientist in the Alexion-Moderna mRNA partnership and held discovery, development, and manufacturing roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics.
Errik Anderson is the founder and CEO of Alloy Therapeutics, a Lexington, Massachusetts biotech he built around a single idea: stop selling drugs and start selling access to the tools that make them. A bioengineer and serial entrepreneur, he has founded or co-founded seven venture-backed biotech companies - Adimab, Alloy, Compass Therapeutics, Alector, Arsanis, and Avitide among them - whose technologies have helped discover more than 90 therapeutic antibodies now approved or in FDA review. Alloy reinvests 100% of its revenue into science and, by design, can never be sold. Outside the lab, Anderson co-owns the New England Free Jacks pro rugby team and has chaired Major League Rugby's Board of Governors.

Russell Beckerman is a biotech entrepreneur and Co-Founder & CEO of Overture Therapeutics, a Cambridge-based company engineering precision antibody medicines targeting obesity and metabolic dysfunction. He previously co-founded 82VS, a venture studio embedded within Alloy Therapeutics that has launched nine drug companies since 2020. His work sits at the intersection of cutting-edge antibody biology, company creation, and the conviction that the next generation of obesity drugs will be antibodies - not peptides.